Publication Date:
2020
Description:
〈p〉Publication date: October 2020〈/p〉
〈p〉〈b〉Source:〈/b〉 Current Opinion in Biotechnology, Volume 65〈/p〉
〈p〉Author(s): Marion Arnaud, Margaux Duchamp, Sara Bobisse, Philippe Renaud, George Coukos, Alexandre Harari〈/p〉
〈div〉〈p〉Among immune correlates of clinical responses, tumor-specific neoantigens took the spotlight as relevant targets for cancer immunotherapy. The implementation of pipelines for personalized cancer therapy remains challenging due to the privacy, that is patient-specificity, of neoantigens and the low-frequency of neoantigen-specific T cells in blood and tumor samples. To overcome these obstacles, recent developments in the field of biotechnology have allowed the multiplexed identification of neoepitope-specific T cells. This review addresses the pros and cons of conventional neoantigen screening methodologies and highlights the current as well as the prospective biotechnological opportunities in the field.〈/p〉〈/div〉
〈h5〉Graphical abstract〈/h5〉
〈div〉〈p〉〈figure〉〈img src="https://ars.els-cdn.com/content/image/1-s2.0-S0958166919301521-fx1.jpg" width="301" alt="Graphical abstract for this article" title=""〉〈/figure〉〈/p〉〈/div〉
Print ISSN:
0958-1669
Electronic ISSN:
1879-0429
Topics:
Biology
,
Medicine
,
Process Engineering, Biotechnology, Nutrition Technology
Permalink
